



Press release

Danderyd, July 9, 2001

Decision on authorisation for the Board of Biolight International AB, July 9, 2001.

The extraordinary general meeting of Biolight International AB has today resolved to authorise the board to decide about new issues, at one or several occasions up to the next annual general meeting, leading to a total maximum issue of 20,000,000 shares of series A or B.

New issues, within the limits mentioned above, may be floated both as issues of shares and as convertible debt instruments or debt instruments with subscription warrants for new shares. At such issues, payment in kind should be allowed. An issue with or without deviation from the shareholders' subscription privilege should be allowed; in the case of deviation from the shareholders' subscription privilege, the issue should target a limited number of Swedish and international institutional and industrial investors.

The reason for this possibility of deviating from the shareholders' preferential rights is to create a readiness for quickly providing the company with more capital. The issue price should be based on market evaluations.

Danderyd, July 9, 2001

The Board of Directors of Biolight International AB (publ)

For further information, please contact:

Christer Wallin, president, Biolight International AB, tel. +46-(0)8-622 52 70

Biolight International AB is a medical technology company, offering its customers, patients, as well as nursing staff and authorities, various products and services, based on the company's patented method for the use of pulsating, monochromatic light. In this way, the company wishes to improve the quality of life for the patients and significantly reduce the time to healing as well as treatment costs. Through systematically executed clinical trials, Biolight is gradually extending its scientific basis to secure the method within the field of health care. During the past few years, Biolight has focused on a small number of indication areas grouped around wound healing.

For further information, please visit Biolight's home page at www.biolight.se